BioSpace Global Roundup: Cevec Licenses AAV Program to Biogen
The Pharma Data
JANUARY 13, 2021
Food and Drug Administration gave it the green light to initiate a Phase III study of tesamorelin for the treatment of adults with Nonalcoholic Steatohepatitis (NASH) with liver fibrosis. Vivity received FDA approval in February 2020. provided an update on its ongoing NASH program. This week, the company said the U.S.
52 
Let's personalize your content